Logo

F-star Entered into License Agreement with Takeda for Immuno-Oncology Bispecific Antibody to Treat Cancer

Share this
F-star Entered into License Agreement with Takeda for Immuno-Oncology Bispecific Antibody to Treat Cancer

F-star Entered into License Agreement with Takeda for Immuno-Oncology Bispecific Antibody to Treat Cancer

Shots:

  • F-star to receive a $1M up front license fee & will be also eligible to receive ~$40M upon the achievement of milestones along with royalties on annual net sales
  • Under the terms of the agreement, Takeda gets an exclusive royalty-bearing license globally to research, develop, and commercialize a bispecific Ab against an immuno-oncology target for the treatment of cancer by using F-star’s Fcab and mAb2 platforms & will lead the research, development, and commercialization activities
  • The collaboration will use Fcab technology to diversify and accelerate Takeda’s gamma delta (γδ) T cell engager portfolio to develop therapies for cancer patients

Ref: GlobalNewswire | Image: Takeda

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions